Analyst firms · BTIG · IART
BTIG IART price target and rating history
Integra LifeSciences Holdings Corporation (IART) · Health Care
BTIG rates Integra LifeSciences Holdings Corporation (IART) Neutral with a $22 price target, as of its latest action on Oct 7, 2024. It has published 3 rating actions on IART since September 2021, including 1 upgrade and 2 downgrades. Across 4 firms with a IART price target in the last 12 months, the median target is $19.
- Current rating
- Neutral
- Price target
- $22
- Median target, all firms
- $19
- Actions on IART
- 3
Every BTIG rating on IART
- Oct 7, 2024
- Jul 30, 2024
- Sep 15, 2021DowngradeBTIG downgrades to Neutral from Buy
How other firms rate IART
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $19 | Jul 28, 2026 |
| BMO Capital Markets | Market Perform | $19 | Jul 9, 2026 |
| Argus Research | Buy | $25 | Jun 18, 2026 |
| Citigroup | Neutral | $16 | May 28, 2026 |
Questions about BTIG and IART
- What is BTIG's price target for IART?
- BTIG's latest stated price target for Integra LifeSciences Holdings Corporation (IART) is $22, from its action on Jul 30, 2024.
- What is BTIG's rating on IART?
- BTIG rates IART Neutral, a neutral rating, as of Oct 7, 2024.
- When did BTIG last change its view on IART?
- On Oct 7, 2024, BTIG upgrades to Neutral from Sell.
- How does BTIG's IART target compare with other analysts?
- Across 4 firms with a IART price target in the last 12 months, the median target is $19.
More IART rating histories
All BTIG ratingsIART news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.